All articles by William Newton

William Newton is a Senior Reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing on clinical trial design, healthcare business and regulation, and new technologies. Now based in New York City, he previously covered diabetes drug development at Close Concerns’ industry-facing publication in San Francisco. William holds a BA in Economics from Williams College.

William Newton


Alzheimer’s disease: major drug trial results to watch in 2022 and beyond

Three Phase III trials in Alzheimer’s disease targeting amyloid will seek a different fate than Biogen’s Aduhelm, while a fourth Phase III study looks to breakthrough with a novel mechanism.

Looming Amylyx drug approval decision renews debate over ALS endpoints

With the FDA’s decision on Amylyx’s AMX-0035 fast approaching, we dive into tensions over ALS endpoints and major drug trials to watch.

Getting real: who is leading the real-world data charge with clinical trials?

In an exclusive analysis, Clinical Trials Arena breaks down the trends and strategies driving the recent growth in real-world evidence studies.

Decentralised regulation: What do FDA remote assessments mean for sponsors?

With FDA remote regulatory assessments (RRAs) officially here to stay, sponsors must keep up with the remote revolution or risk falling behind.

Mapping Endpoints in Psoriasis: beyond the mirage of complete skin clearance

As plaque psoriasis treatments prove more effective, the field is debating new approaches to measure efficacy and address remaining unmet need.

AIM ImmunoTech outlines Phase II study plans for long Covid fatigue

AIM ImmunoTech leadership offers new details on a potential Phase II trial of Ampligen in long Covid patients with chronic fatigue.

Ashvattha previews plans for long Covid trial in mid-2023

In an exclusive, Ashvattha Therapeutics CEO Jeff Cleland discusses a potential trial of OP-101 in long Covid patients experiencing chronic inflammation.

Plaque psoriasis and psoriatic arthritis: trials to watch in 2022

Four Phase II and III trials in plaque psoriasis or psoriatic arthritis have results expected in 2H 2022, and five Phase III studies have expected completions.

Axcella previews long Covid registrational trial plans in UK and US

Axcella in discussions with UK regulators for a new long Covid trial, CEO says, following Phase IIa results announced this morning.

Alzheimer’s disease: charting amyloid theory trials amidst another controversy

After reports of possible image fabrication in studies supporting the amyloid theory for Alzheimer’s disease, we break down the slate of ongoing trials.